Adjuvant Therapy of Melanoma

Area of Science:

• Oncology
• Immunology
• Dermatology

Background:

• Melanoma incidence is rising, particularly in younger women and older men.
• Advances in understanding melanoma tumorigenesis involve MAPK pathway inhibitors and immune checkpoints (CTLA-4, PD-1/PD-L1).
• Most patients present with non-metastatic disease, managed by surgery and adjuvant therapy.

Purpose of the Study:

• To review evidence supporting adjuvant high-dose interferon alfa-2b (HDI) in high-risk melanoma.
• To discuss other evaluated adjuvant treatment modalities for melanoma.

Main Methods:

• Review of existing literature and clinical trial data on adjuvant HDI for melanoma.
• Analysis of studies evaluating vaccines, chemotherapy, and radiotherapy as adjuvant treatments.

Main Results:

• High-dose interferon alfa-2b (HDI) remains a primary adjuvant therapy for resected high-risk melanoma.
• Evidence supporting HDI efficacy in specific patient subgroups is presented.
• Other modalities like vaccines, chemotherapy, and radiotherapy have been explored with varying outcomes.

Conclusions:

• Adjuvant HDI is a significant treatment option for high-risk melanoma patients post-resection.
• Further research into optimizing adjuvant therapies, including novel approaches, is warranted.
• Understanding melanoma tumorigenesis guides the development of targeted and immune-based treatments.